Autoantibodies Against Gad65Rather Than Gad67Precede the Onset of Type 1 Diabetes
| Autor: | Rjasanowski I, Michael Schlosser, Heinz Haubruck, Ludwig Mauch, Manfred Ziegler, K. D. Kohnert, Michaelis D, Lühder F |
|---|---|
| Rok vydání: | 1994 |
| Předmět: |
Adult
Male endocrine system Adolescent endocrine system diseases Immunology Glutamate decarboxylase Sensitivity and Specificity Radioligand Assay Antigen Risk Factors medicine Humans Immunology and Allergy Longitudinal Studies Risk factor Child Autoantibodies Autoimmune disease Type 1 diabetes Glutamate Decarboxylase business.industry Autoantibody nutritional and metabolic diseases Radioimmunoassay Middle Aged medicine.disease Isoenzymes Cross-Sectional Studies Diabetes Mellitus Type 1 Child Preschool Female Beta cell business Biomarkers |
| Zdroj: | Autoimmunity. 19:71-80 |
| ISSN: | 1607-842X 0891-6934 |
| DOI: | 10.3109/08916939409009534 |
| Popis: | The enzyme glutamate decarboxylase (GAD) is considered one of the major Beta cell antigens in Type 1 diabetes mellitus. The GAD autoantibody (GAD-AAb) prevalence in newly diagnosed Type 1 diabetic patients has been described up to 80%, depending on the detection method used. The aim of this study was to evaluate a simple, specific, and sensitive radioimmunoassay (RIA) method for detection of AAb against both isoforms of the enzyme, GAD65 and GAD67, in a cross-sectional study using sera from newly diagnosed Type 1 diabetic patients and in a longitudinal study using sera from prediabetic patients and individuals at risk of developing the disease. The 125I-labelled full-length human recombinant proteins of GAD65 and GAD67 expressed in SF9 cells were used as the antigen source. The prevalence of GAD65-AAb in newly diagnosed Type 1 diabetic patients was found to be 73% (112/153), in contrast to 19% (14/72) of GAD67-AAb. Only one patient produced AAb restricted to GAD67. Furthermore, GAD65-AAb could also be detected in 73% (11/15) of prediabetic patients (up to 122 months before clinical manifestation of the disease), whereas only 27% (4/15) of them were positive for GAD67-AAb. In the group at risk of developing Type 1 diabetes, these prevalences were 77% (10/13) and 46% (6/13), respectively. In all GAD67-AAb-positive patients investigated in the longitudinal study, AAb to GAD65 were detectable. In 47% of patients positive for both GAD65-AAb and ICA, the GAD65-AAb appeared by up to 46 months before the occurrence of ICA was detected. The data illustrated that GAD65 is the main immunogenic isoform of the enzyme in the preclinical and clinical stages. The RIA detecting AAb against this isoform may facilitate the screening for individuals at risk of developing the disease. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|